Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 21 days ago
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Share to Feed
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (ATRA Research Report) and Embecta Corporation...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
StockNews.com cut shares of Atara Biotherapeutics (NASDAQ:ATRA - Free Report) from a hold rating to a sell rating in a report released on Thursday morning. Atara Biotherapeutics Stock Down 0.9...
Analysts fell to the sidelines weighing in on Affimed (AFMD Research Report) and Atara Biotherapeutics (ATRA Research Report) with neutral rati...
Atara Biotherapeutics ( NASDAQ:ATRA ) Full Year 2023 Results Key Financial Results Net loss: US$276.1m (loss widened by...
StockNews.com lowered shares of Atara Biotherapeutics (NASDAQ:ATRA Free Report) from a hold rating to a sell rating in a research note issued to investors on Thursday.
Atara Biotherapeutics...
Atara Biotherapeutics (ATRA) just unveiled an announcement. Eric Dobmeier, a board member of Atara Biotherapeutics, Inc., has decided not to seek r...
Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Accounting & Financial Operations category. Atara Biotherapeutics Inc. faces subs...